Ulrich M Zanger

List of Publications by Year
in descending order

197	22,945	7096 78	11308 136
papers	citations	h-index	g-index

228	228	228	18775
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Triâ€Allelic Haplotypes Determine and Differentiate Functionally Normal Allele CYP2D6*2 and Impaired Allele CYP2D6*41. Clinical Pharmacology and Therapeutics, 2021, 109, 1256-1264.	4.7	7
2	Differential effects on human cytochromes P450 by CRISPR/Cas9-induced genetic knockout of cytochrome P450 reductase and cytochrome b5 in HepaRG cells. Scientific Reports, 2021, 11, 1000.	3.3	6
3	Polycyclic Aromatic Hydrocarbons Activate the Aryl Hydrocarbon Receptor and the Constitutive Androstane Receptor to Regulate Xenobiotic Metabolism in Human Liver Cells. International Journal of Molecular Sciences, 2021, 22, 372.	4.1	26
4	P450 Monooxygenase System. , 2021, , 1211-1219.		0
5	Effects of Diminished NADPH:cytochrome P450 Reductase in Human Hepatocytes on Lipid and Bile Acid Homeostasis. Frontiers in Pharmacology, 2021, 12, 769703.	3.5	6
6	Copy number variation profiling in pharmacogenes using panel-based exome resequencing and correlation to human liver expression. Human Genetics, 2020, 139, 137-149.	3.8	9
7	MiR-155 and other microRNAs downregulate drug metabolizing cytochromes P450 in inflammation. Biochemical Pharmacology, 2020, 171, 113725.	4.4	32
8	P450 Monooxygenase System. , 2020, , 1-9.		0
9	Factors Affecting Interindividual Variability of Hepatic UGT2B17 Protein Expression Examined Using a Novel Specific Monoclonal Antibody. Drug Metabolism and Disposition, 2019, 47, 444-452.	3.3	8
10	The azole fungicide tebuconazole affects human CYP1A1 and CYP1A2 expression by an aryl hydrocarbon receptor-dependent pathway. Food and Chemical Toxicology, 2019, 123, 481-491.	3.6	34
11	A New Panel-Based Next-Generation Sequencing Method for ADME Genes Reveals Novel Associations of Common and Rare Variants With Expression in a Human Liver Cohort. Frontiers in Genetics, 2019, 10, 7.	2.3	37
12	Unexpected Effects of Propiconazole, Tebuconazole, and Their Mixture on the Receptors CAR and PXR in Human Liver Cells. Toxicological Sciences, 2018, 163, 170-181.	3.1	33
13	Direct Quantification of Cytochromes P450 and Drug Transportersâ€"A Rapid, Targeted Mass Spectrometry-Based Immunoassay Panel for Tissues and Cell Culture Lysates. Drug Metabolism and Disposition, 2018, 46, 387-396.	3.3	32
14	The formation of estrogen-like tamoxifen metabolites and their influence on enzyme activity and gene expression of ADME genes. Archives of Toxicology, 2018, 92, 1099-1112.	4.2	18
15	Regulation of Drug Metabolism by the Interplay of Inflammatory Signaling, Steatosis, and Xeno-Sensing Receptors in HepaRG Cells. Drug Metabolism and Disposition, 2018, 46, 326-335.	3.3	29
16	Î²-Defensin 1 Is Prominent in the Liver and Induced During Cholestasis by Bilirubin and Bile Acids via Farnesoid X Receptor and Constitutive Androstane Receptor. Frontiers in Immunology, 2018, 9, 1735.	4.8	12
17	Epigenetics and MicroRNAs in Pharmacogenetics. Advances in Pharmacology, 2018, 83, 33-64.	2.0	15
18	Methyleugenol DNA adducts in human liver are associated with SULT1A1 copy number variations and expression levels. Archives of Toxicology, 2017, 91, 3329-3339.	4.2	30

#	Article	IF	Citations
19	Regulation of drug metabolism and toxicity by multiple factors of genetics, epigenetics, lncRNAs, gut microbiota, and diseases: a meeting report of the 21st International Symposium on Microsomes and Drug Oxidations (MDO). Acta Pharmaceutica Sinica B, 2017, 7, 241-248.	12.0	20
20	Membrane Associated Progesterone Receptors: Promiscuous Proteins with Pleiotropic Functions â€“ Focus on Interactions with Cytochromes P450. Frontiers in Pharmacology, 2017, 8, 159.	3.5	80
21	Effect of Genetic Variability in the CYP4F2, CYP4F11, and CYP4F12 Genes on Liver mRNA Levels and Warfarin Response. Frontiers in Pharmacology, 2017, 8, 323.	3.5	21
22	Editorial: Role of Protein-Protein Interactions in Metabolism: Genetics, Structure, Function. Frontiers in Pharmacology, 2017, 8, 881.	3.5	5
23	Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting. Clinical Pharmacology and Therapeutics, 2016, 99, 172-185.	4.7	146
24	Association between CYP2E1 polymorphisms and risk of differentiated thyroid carcinoma. Archives of Toxicology, 2016, 90, 3099-3109.	4.2	9
25	Genomewide comparison of the inducible transcriptomes of nuclear receptors CAR, PXR and PPARÎ± in primary human hepatocytes. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2016, 1859, 1218-1227.	1.9	67
26	Inflammatory regulation of steroid sulfatase: A novel mechanism to control estrogen homeostasis and inflammation in chronic liver disease. Journal of Hepatology, 2016, 64, 44-52.	3.7	31
27	Gene copy number variation analysis reveals dosage-insensitive expression of CYP2E1. Pharmacogenomics Journal, 2016, 16, 551-558.	2.0	13
28	Rifampin enhances cytochrome P450 (CYP) 2B6-mediated efavirenz 8-hydroxylation in healthy volunteers. Drug Metabolism and Pharmacokinetics, 2016, 31, 107-116.	2.2	14
29	Variability in hepatic expression of organic anion transporter 7/SLC22A9, a novel pravastatin uptake transporter: impact of genetic and regulatory factors. Pharmacogenomics Journal, 2016, 16, 341-351.	2.0	34
30	Coordinating Role of RXRÎ± in Downregulating Hepatic Detoxification during Inflammation Revealed by Fuzzy-Logic Modeling. PLoS Computational Biology, 2016, 12, e1004431.	3.2	27
31	Model-Based Characterization of Inflammatory Gene Expression Patterns of Activated Macrophages. PLoS Computational Biology, 2016, 12, e1005018.	3.2	40
32	Pathobiochemical signatures of cholestatic liver disease in bile duct ligated mice. BMC Systems Biology, 2015, 9, 83.	3.0	51
33	LEMming: A Linear Error Model to Normalize Parallel Quantitative Real-Time PCR (qPCR) Data as an Alternative to Reference Gene Based Methods. PLoS ONE, 2015, 10, e0135852.	2.5	22
34	Peroxisome proliferator-activated receptor alpha, PPARÎ±, directly regulates transcription of cytochrome P450 CYP2C8. Frontiers in Pharmacology, 2015, 6, 261.	3.5	29
35	Targeted epigenome editing of an endogenous locus with chromatin modifiers is not stably maintained. Epigenetics and Chromatin, 2015, 8, 12.	3.9	77
36	Inflammation-Associated MicroRNA-130b Down-Regulates Cytochrome P450 Activities and Directly Targets CYP2C9. Drug Metabolism and Disposition, 2015, 43, 884-888.	3.3	69

#	Article	IF	Citations
37	Comparative Analysis and Functional Characterization of HC-AFW1 Hepatocarcinoma Cells: Cytochrome P450 Expression and Induction by Nuclear Receptor Agonists. Drug Metabolism and Disposition, 2015, 43, 1781-1787.	3.3	15
38	Oncostatin M regulates SOCS3 mRNA stability via the MEKâ€“ERK1/2-pathway independent of p38MAPK/MK2. Cellular Signalling, 2015, 27, 555-567.	3.6	23
39	Role of ABC Transporters in Fluoropyrimidine-Based Chemotherapy Response. Advances in Cancer Research, 2015, 125, 217-243.	5.0	43
40	Human Sterol Regulatory Element-Binding Protein 1a Contributes Significantly to Hepatic Lipogenic Gene Expression. Cellular Physiology and Biochemistry, 2015, 35, 803-815.	1.6	35
41	Activating and Inhibitory Functions of WNT/Î²-Catenin in the Induction of Cytochromes P450 by Nuclear Receptors in HepaRG Cells. Molecular Pharmacology, 2015, 87, 1013-1020.	2.3	34
42	Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncology, The, 2015, 16, 1639-1650.	10.7	277
43	The truncated splice variant of peroxisome proliferator-activated receptor alpha, PPARÎ±-tr, autonomously regulates proliferative and pro-inflammatory genes. BMC Cancer, 2015, 15, 488.	2.6	31
44	Multiplexed Targeted Quantitative Proteomics Predicts Hepatic Glucuronidation Potential. Drug Metabolism and Disposition, 2015, 43, 1331-1335.	3.3	39
45	A Systematic Comparison of the Impact of Inflammatory Signaling on Absorption, Distribution, Metabolism, and Excretion Gene Expression and Activity in Primary Human Hepatocytes and HepaRG Cells. Drug Metabolism and Disposition, 2015, 43, 273-283.	3.3	80
46	Pregnane X receptor activation and silencing promote steatosis of human hepatic cells by distinct lipogenic mechanisms. Archives of Toxicology, 2015, 89, 2089-2103.	4.2	86
47	Isoniazid Mediates the CYP2B6*6 Genotype-Dependent Interaction between Efavirenz and Antituberculosis Drug Therapy through Mechanism-Based Inactivation of CYP2A6. Antimicrobial Agents and Chemotherapy, 2014, 58, 4145-4152.	3.2	23
48	Targeting Nuclear Receptors with Lentivirus-Delivered Small RNAs in Primary Human Hepatocytes. Cellular Physiology and Biochemistry, 2014, 33, 2003-2013.	1.6	14
49	No Activation of Human Pregnane X Receptor by Hyperforin-Related Phloroglucinols. Journal of Pharmacology and Experimental Therapeutics, 2014, 348, 393-400.	2.5	11
50	Genetics, Epigenetics, and Regulation of Drug-Metabolizing Cytochrome P450 Enzymes. Clinical Pharmacology and Therapeutics, 2014, 95, 258-261.	4.7	91
51	Genetic Markers of Toxicity From Capecitabine and Other Fluorouracil-Based Regimens: Investigation in the QUASAR2 Study, Systematic Review, and Meta-Analysis. Journal of Clinical Oncology, 2014, 32, 1031-1039.	1.6	216
52	Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1. Genome Medicine, 2013, 5, 1.	8.2	198
53	Novel CYP2B6 Enzyme Variants in a Rwandese Population: Functional Characterization and Assessment of In Silico Prediction Tools. Human Mutation, 2013, 34, 725-734.	2.5	28
54	Expression Variability of Absorption, Distribution, Metabolism, Excretionâ€“Related MicroRNAs in Human Liver: Influence of Nongenetic Factors and Association with Gene Expression. Drug Metabolism and Disposition, 2013, 41, 1752-1762.	3.3	108

#	Article	IF	Citations
55	ABCC11/MRP8 polymorphisms affect 5-fluorouracil-induced severe toxicity and hepatic expression. Pharmacogenomics, 2013, 14, 1433-1448.	1.3	21
56	TheCYP2B6*6Allele Significantly Alters theN-Demethylation of Ketamine Enantiomers In Vitro. Drug Metabolism and Disposition, 2013, 41, 1264-1272.	3.3	45
57	Omics and Drug Response. Annual Review of Pharmacology and Toxicology, 2013, 53, 475-502.	9.4	130
58	Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. , 2013, 138, 103-141.		2,924
59	Pharmacogenomics of Cytochrome P450 3A4: Recent Progress Toward the â€œMissing Heritabilityâ€• Problem. Frontiers in Genetics, 2013, 4, 12.	2.3	181
60	Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance. Frontiers in Genetics, 2013, 4, 24.	2.3	270
61	Abundance of DNA adducts of methyleugenol, a rodent hepatocarcinogen, in human liver samples. Carcinogenesis, 2013, 34, 1025-1030.	2.8	50
62	Direct Transcriptional Regulation of Human Hepatic Cytochrome P450 3A4 (CYP3A4) by Peroxisome Proliferatorâ€“Activated Receptor Alpha (PPARÎ±). Molecular Pharmacology, 2013, 83, 709-718.	2.3	88
63	Genomics of ADME gene expression: mapping expression quantitative trait loci relevant for absorption, distribution, metabolism and excretion of drugs in human liver. Pharmacogenomics Journal, 2013, 13, 12-20.	2.0	103
64	Molecular Interactions between NAFLD and Xenobiotic Metabolism. Frontiers in Genetics, 2013, 4, 2.	2.3	55
65	Genetic polymorphism of cytochrome P450 2D6 determines oestrogen receptor activity of the major infertility drug clomiphene via its active metabolites. Human Molecular Genetics, 2012, 21, 1145-1154.	2.9	37
66	Cytochrome P450 2B6: function, genetics, and clinical relevance. Drug Metabolism and Drug Interactions, 2012, 27, 185-197.	0.3	78
67	PPARA: A Novel Genetic Determinant of CYP3A4 In Vitro and In Vivo. Clinical Pharmacology and Therapeutics, 2012, 91, 1044-1052.	4.7	131
68	Effect of CYP2B6*6 and CYP2C19*2 genotype on chlorpyrifos metabolism. Toxicology, 2012, 293, 115-122.	4.2	27
69	DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinoma. Genome Medicine, 2011, 3, 82.	8.2	124
70	Inferring statin-induced gene regulatory relationships in primary human hepatocytes. Bioinformatics, 2011, 27, 2473-2477.	4.1	19
71	Paraoxonase (PON1 and PON3) Polymorphisms: Impact on Liver Expression and Atorvastatin-Lactone Hydrolysis. Frontiers in Pharmacology, 2011, 2, 41.	3.5	41
72	MIRNA-DISTILLER: A Stand-Alone Application to Compile microRNA Data from Databases. Frontiers in Genetics, 2011, 2, 39.	2.3	8

#	Article	IF	Citations
73	A systems biology approach to dynamic modeling and inter-subject variability of statin pharmacokinetics in human hepatocytes. BMC Systems Biology, 2011, 5, 66.	3.0	24
74	Transcriptional Profiling of Human Liver Identifies Sex-Biased Genes Associated with Polygenic Dyslipidemia and Coronary Artery Disease. PLoS ONE, 2011, 6, e23506.	2.5	143
75	UDP-Glucuronosyltransferase (UGT) Polymorphisms Affect Atorvastatin Lactonization In Vitro and In Vivo. Clinical Pharmacology and Therapeutics, 2010, 87, 65-73.	4.7	98
76	Pharmacogenetics â€“ challenges and opportunities ahead. Frontiers in Pharmacology, 2010, 1, 112.	3.5	12
77	Pathway-Targeted Pharmacogenomics of CYP1A2 in Human Liver. Frontiers in Pharmacology, 2010, 1, 129.	3.5	81
78	Effect ofCYP2B6,ABCB1, andCYP3A5Polymorphisms on Efavirenz Pharmacokinetics and Treatment Response: An AIDS Clinical Trials Group Study. Journal of Infectious Diseases, 2010, 202, 717-722.	4.0	127
79	Profiling Induction of Cytochrome P450 Enzyme Activity by Statins Using a New Liquid Chromatography-Tandem Mass Spectrometry Cocktail Assay in Human Hepatocytes. Drug Metabolism and Disposition, 2010, 38, 1589-1597.	3.3	81
80	A Predominate Role of CYP1A2 for the Metabolism of Nabumetone to the Active Metabolite, 6-Methoxy-2-naphthylacetic Acid, in Human Liver Microsomes. Drug Metabolism and Disposition, 2009, 37, 1017-1024.	3.3	42
81	Pharmacogenomics of human liver cytochrome P450 oxidoreductase: multifactorial analysis and impact on microsomal drug oxidation. Pharmacogenomics, 2009, 10, 579-599.	1.3	125
82	Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology, 2009, 50, 1227-1240.	7.3	316
83	RNA-Interference Approach to Study Functions of NADPHÃ¢Â€Â‰:Ã¢Â€Â‰Cytochrome P450 Oxidoreductase in Human Hepatocytes. Chemistry and Biodiversity, 2009, 6, 2084-2091.	2.1	9
84	Mass spectrometryâ€based absolute quantification of microsomal cytochrome P450 2D6 in human liver. Proteomics, 2009, 9, 2313-2323.	2.2	70
85	Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Analytical and Bioanalytical Chemistry, 2008, 392, 1093-1108.	3.7	510
86	Functional study of the 830C>G polymorphism of the human carboxylesterase 2 gene. Cancer Chemotherapy and Pharmacology, 2008, 61, 481-488.	2.3	24
87	Non-synonymous polymorphisms in the human SLCO1B1 gene: an in vitro analysis of SNPÂc.1929A>C. Molecular Genetics and Genomics, 2008, 279, 149-157.	2.1	9
88	6-mercaptopurine and 9-(2-phosphonyl-methoxyethyl) adenine (PMEA) transport altered by two missense mutations in the drug transporter gene ABCC4. Human Mutation, 2008, 29, 659-669.	2.5	46
89	Variability in human hepatic MRP4 expression: influence of cholestasis and genotype. Pharmacogenomics Journal, 2008, 8, 42-52.	2.0	83
90	Distinction between Human Cytochrome P450 (CYP) Isoforms and Identification of New Phosphorylation Sites by Mass Spectrometry. Journal of Proteome Research, 2008, 7, 4678-4688.	3.7	57

#	Article	IF	Citations
91	Pharmacogenetics of Anti-HIV Drugs. Annual Review of Pharmacology and Toxicology, 2008, 48, 227-256.	9.4	68
92	Highly Multiplexed Genotyping of Thiopurine S-Methyltransferase Variants Using MALDI-TOF Mass Spectrometry: Reliable Genotyping in Different Ethnic Groups. Clinical Chemistry, 2008, 54, 1637-1647.	3.2	103
93	Role of Genetic and Nongenetic Factors for Fluorouracil Treatment-Related Severe Toxicity: A Prospective Clinical Trial by the German 5-FU Toxicity Study Group. Journal of Clinical Oncology, 2008, 26, 2131-2138.	1.6	360
94	Aberrant Splicing Caused by Single Nucleotide Polymorphism c.516G>T [Q172H], a Marker of CYP2B6*6, Is Responsible for Decreased Expression and Activity of CYP2B6 in Liver. Journal of Pharmacology and Experimental Therapeutics, 2008, 325, 284-292.	2.5	201
95	Carbonyl Reductase 1 Is a Predominant Doxorubicin Reductase in the Human Liver. Drug Metabolism and Disposition, 2008, 36, 2113-2120.	3.3	158
96	Chapter 8. The CYP2D Subfamily. Issues in Toxicology, 2008, , 241-275.	0.1	3
97	P450 Mono-oxygenase System. , 2008, , 921-927.		0
98	Molecular Mechanism of Basal CYP3A4 Regulation by Hepatocyte Nuclear Factor 4Î±: Evidence for Direct Regulation in the Intestine. Drug Metabolism and Disposition, 2007, 35, 946-954.	3.3	43
99	A Natural Variant of the Heme-Binding Signature (R441C) Resulting in Complete Loss of Function of CYP2D6. Drug Metabolism and Disposition, 2007, 35, 1247-1250.	3.3	22
100	Sex-dependent genetic markers of CYP3A4 expression and activity in human liver microsomes. Pharmacogenomics, 2007, 8, 443-453.	1.3	63
101	Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism inÂvitro. Pharmacogenomics, 2007, 8, 547-558.	1.3	196
102	Breast Cancer Treatment Outcome With Adjuvant Tamoxifen Relative to Patient CYP2D6 and CYP2C19 Genotypes. Journal of Clinical Oncology, 2007, 25, 5187-5193.	1.6	424
103	Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenomics, 2007, 8, 743-759.	1.3	252
104	MALDI-TOF Mass Spectrometry for Multiplex Genotyping of CYP2B6 Single-Nucleotide Polymorphisms. Clinical Chemistry, 2007, 53, 24-33.	3.2	37
105	Predictive Value of Known and Novel Alleles of CYP2B6 for Efavirenz Plasma Concentrations in HIV-infected Individuals. Clinical Pharmacology and Therapeutics, 2007, 81, 557-566.	4.7	240
106	Selective Induction of Human Hepatic Cytochromes P450 2B6 and 3A4 by Metamizole. Clinical Pharmacology and Therapeutics, 2007, 82, 265-274.	4.7	57
107	Genetic signature consistent with selection against the CYP3A4*1B allele in non-African populations. Pharmacogenetics and Genomics, 2006, 16, 59-71.	1.5	38
108	Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP 2988G>A: evidence for modulation of splicing events. Pharmacogenetics and Genomics, 2006, 16, 755-766.	1.5	80

#	Article	IF	Citations
109	A silent mutation (2939G>A, exon 6; CYP2D6*59) leading to impaired expression and function of CYP2D6. Pharmacogenetics and Genomics, 2006, 16, 767-770.	1.5	18
110	Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics. Pharmacogenetics and Genomics, 2006, 16, 801-808.	1.5	96
111	Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: Effect of induction by rifampin and ethnicity. Clinical Pharmacology and Therapeutics, 2006, 80, 75-84.	4.7	86
112	Transcriptional profiling of genes induced in the livers of patients treated with carbamazepine. Clinical Pharmacology and Therapeutics, 2006, 80, 440-456.e7.	4.7	113
113	Interindividual variability of canalicular ATP-binding-cassette (ABC)-transporter expression in human liver. Hepatology, 2006, 44, 62-74.	7.3	211
114	Three novel thiopurine S-methyltransferase allelic variants (TPMT*20, *21, *22) â€“ association with decreased enzyme function. Human Mutation, 2006, 27, 976-976.	2.5	55
115	Three haplotypes associated with CYP2A6 phenotypes in Caucasians. Pharmacogenetics and Genomics, 2005, 15, 609-624.	1.5	86
116	Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenetics and Genomics, 2005, 15, 861-873.	1.5	232
117	Limited Association of the 2988g>a Single Nucleotide Polymorphism with CYP2D6*41 in Black Subjects: Reply*. Clinical Pharmacology and Therapeutics, 2005, 77, 230-231.	4.7	9
118	GSTP1 and MDR1 Genotypes and Central Nervous System Relapse in Childhood Acute Lymphoblastic Leukemia. International Journal of Hematology, 2005, 81, 39-44.	1.6	47
119	Inhibition of human CYP2B6 by N,Nâ€²,Nâ€³-triethylenethiophosphoramide is irreversible and mechanism-based. Biochemical Pharmacology, 2005, 69, 517-524.	4.4	37
120	Comprehensive analysis of pyrimidine metabolism in 450 children with unspecific neurological symptoms using highâ€“pressure liquid chromatographyâ€“electrospray ionization tandem mass spectrometry. Journal of Inherited Metabolic Disease, 2005, 28, 1109-1122.	3.6	19
121	Contribution of CYP3A5 to the in Vitro Hepatic Clearance of Tacrolimus. Clinical Chemistry, 2005, 51, 1374-1381.	3.2	187
122	Thiopurine Methyltransferase (<EMPH TYPE="ITAL">TPMT</EMPH>) Genotype and Early Treatment Response to Mercaptopurine in Childhood Acute Lymphoblastic Leukemia. JAMA - Journal of the American Medical Association, 2005, 293, 1485.	7.4	248
123	Impact of Genetic Polymorphism in Relation to Other Factors on Expression and Function of Human Drug-Metabolizing P450s. Toxicology Mechanisms and Methods, 2005, 15, 121-124.	2.7	17
124	A Natural CYP2B6 TATA Box Polymorphism (â€“82Tâ†’C) Leading to Enhanced Transcription and Relocation of the Transcriptional Start Site. Molecular Pharmacology, 2005, 67, 1772-1782.	2.3	106
125	ABCB1 Genotype of the Donor but Not of the Recipient Is a Major Risk Factor for Cyclosporine-Related Nephrotoxicity after Renal Transplantation. Journal of the American Society of Nephrology: JASN, 2005, 16, 1501-1511.	6.1	208
126	Multiple Novel Nonsynonymous CYP2B6 Gene Polymorphisms in Caucasians: Demonstration of Phenotypic Null Alleles. Journal of Pharmacology and Experimental Therapeutics, 2004, 311, 34-43.	2.5	128

#	Article	IF	Citations
127	Potent Mechanism-Based Inhibition of Human CYP2B6 by Clopidogrel and Ticlopidine. Journal of Pharmacology and Experimental Therapeutics, 2004, 308, 189-197.	2.5	236
128	The Induction of Cytochrome P450 3A5 (CYP3A5) in the Human Liver and Intestine Is Mediated by the Xenobiotic Sensors Pregnane X Receptor (PXR) and Constitutively Activated Receptor (CAR). Journal of Biological Chemistry, 2004, 279, 38379-38385.	3.4	162
129	Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn-Schmiedeberg's Archives of Pharmacology, 2004, 369, 23-37.	3.0	687
130	Limited contribution of CYP3A5 to the hepatic 6?-hydroxylation of testosterone. Naunyn-Schmiedeberg's Archives of Pharmacology, 2004, 370, 71-7.	3.0	13
131	A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects*1. Clinical Pharmacology and Therapeutics, 2004, 76, 128-138.	4.7	160
132	Comprehensive analysis of thiopurine S-methyltransferase phenotypeâ€“genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics and Genomics, 2004, 14, 407-417.	5.7	393
133	Genetic polymorphisms in the multidrug resistance-associated protein 3 (ABCC3, MRP3) gene and relationship to its mRNA and protein expression in human liver. Pharmacogenetics and Genomics, 2004, 14, 155-164.	5.7	113
134	Sex is a major determinant of CYP3A4 expression in human liver. Hepatology, 2003, 38, 978-988.	7.3	426
135	CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real-rime PCR. Human Mutation, 2003, 22, 476-485.	2.5	142
136	Sensitive method for the quantification of urinary pyrimidine metabolites in healthy adults by gas chromatographyâ€“tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2003, 791, 371-380.	2.3	18
137	Large interindividual variability in the in vitro formation of tamoxifen metabolites related to the development of genotoxicity. British Journal of Clinical Pharmacology, 2003, 57, 105-111.	2.4	21
138	A novel TPMT missense mutation associated with TPMT deficiency in a 5-year-old boy with ALL. Leukemia, 2003, 17, 1422-1424.	7.2	49
139	Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes. Pharmacogenomics Journal, 2003, 3, 335-342.	2.0	84
140	Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology, 2003, 124, 26-33.	1.3	309
141	Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine. Gut, 2003, 52, 140-142.	12.1	134
142	Influence of Omeprazole on Multidrug Resistance Protein 3 Expression in Human Liver. Journal of Pharmacology and Experimental Therapeutics, 2003, 304, 524-530.	2.5	46
143	Mutational Analysis of the Human Dihydropyrimidine Dehydrogenase Gene by Denaturing High-Performance Liquid Chromatography. Genetic Testing and Molecular Biomarkers, 2003, 7, 97-105.	1.7	20
144	Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics and Genomics, 2003, 13, 619-626.	5.7	236

#	Article	IF	Citations
145	Sex is a major determinant of CYP3A4 expression in human liver. Hepatology, 2003, 38, 978-988.	7.3	244
146	V79 Chinese hamster cells genetically engineered for polymorphic cytochrome P450 2D6 and their predictive value for humans. ALTEX: Alternatives To Animal Experimentation, 2003, 20, 143-54.	1.5	14
147	Interindividual Variability and Tissue-Specificity in the Expression of Cytochrome P450 3A mRNA. Drug Metabolism and Disposition, 2002, 30, 1108-1114.	3.3	282
148	Detection of single nucleotide polymorphisms in CYP2B6 gene. Methods in Enzymology, 2002, 357, 45-53.	1.0	9
149	Molecular Mechanisms of Polymorphic CYP3A7 Expression in Adult Human Liver and Intestine. Journal of Biological Chemistry, 2002, 277, 24280-24288.	3.4	164
150	A Naturally Occurring Mutation in the SLC21A6Gene Causing Impaired Membrane Localization of the Hepatocyte Uptake Transporter. Journal of Biological Chemistry, 2002, 277, 43058-43063.	3.4	127
151	Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics and Genomics, 2002, 12, 429-436.	5.7	236
152	Expression polymorphism of the blood???brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease. Pharmacogenetics and Genomics, 2002, 12, 529-534.	5.7	176
153	Pharmacokinetic differences between ethnic groups. Lancet, The, 2002, 359, 78-79.	13.7	1
154	Discriminative Quantification of Cytochrome P4502D6 and 2D7/8 Pseudogene Expression by TaqMan Real-Time Reverse Transcriptase Polymerase Chain Reaction. Analytical Biochemistry, 2002, 300, 121-131.	2.4	22
155	The influence ofCYP2B6,CYP2C9andCYP2D6genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver. British Journal of Clinical Pharmacology, 2002, 54, 157-167.	2.4	118
156	Genetic polymorphisms of glutathione S-transferase A1, the major glutathione S-transferase in human liver: Consequences for enzyme expression and busulfan conjugation*. Clinical Pharmacology and Therapeutics, 2002, 71, 479-487.	4.7	73
157	Overlapping but distinct specificities of anti-liver-kidney microsome antibodies in autoimmune hepatitis type II and hepatitis C revealed by recombinant native CYP2D6 and novel peptide epitopes. Clinical and Experimental Immunology, 2001, 118, 290-297.	2.6	41
158	Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet, The, 2001, 358, 383-384.	13.7	260
159	High-Throughput Genotyping of Thiopurine S-Methyltransferase by Denaturing HPLC. Clinical Chemistry, 2001, 47, 548-555.	3.2	84
160	Microsomal Epoxide Hydrolase Expression as a Predictor of Tamoxifen Response in Primary Breast Cancer: A Retrospective Exploratory Study With Long-Term Follow-Up. Journal of Clinical Oncology, 2001, 19, 3-9.	1.6	22
161	Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain. Pharmacogenetics and Genomics, 2001, 11, 237-245.	5.7	136
162	Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics and Genomics, 2001, 11, 573-585.	5.7	268

#	Article	IF	Citations
163	The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics and Genomics, 2001, 11, 773-779.	5.7	608
164	Influence of CYP2D6 genotype and medication on the sparteine metabolic ratio of psychiatric patients. European Journal of Clinical Pharmacology, 2001, 57, 289-295.	1.9	15
165	Distribution of microsomal epoxide hydrolase in humans: an immunohistochemical study in normal tissues, and benign and malignant tumours. The Histochemical Journal, 2001, 33, 329-336.	0.6	47
166	High-throughput genotyping of thiopurine S-methyltransferase by denaturing HPLC. Clinical Chemistry, 2001, 47, 548-55.	3.2	25
167	Elucidation of the genetic basis of the common â€˜intermediate metabolizerâ€™ phenotype for drug oxidation by CYP2D6. Pharmacogenetics and Genomics, 2000, 10, 577-581.	5.7	196
168	Identification of the human cytochromes P450 involved in the oxidative metabolism of â€œEcstasyâ€•related designer drugs. Biochemical Pharmacology, 2000, 59, 1563-1571.	4.4	183
169	Immunohistochemical detection of microsomal epoxide hydrolase in human synovial tissue. The Histochemical Journal, 1999, 31, 645-649.	0.6	3
170	Expression of intestinal drug-metabolizing enzymes in patients with chronic inflammatory bowel disease. Current Therapeutic Research, 1998, 59, 556-563.	1.2	16
171	Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics and Genomics, 1998, 8, 15-26.	5.7	281
172	Analysis of CYP2D6 expression in human lung: implications for the association between CYP2D6 activity and susceptibility to lung cancer. Pharmacogenetics and Genomics, 1997, 7, 295-302.	5.7	26
173	MOLECULAR MECHANISMS OF GENETIC POLYMORPHISMS OF DRUG METABOLISM. Annual Review of Pharmacology and Toxicology, 1997, 37, 269-296.	9.4	499
174	Functional properties of CYP2D6 1 (wild-type) and CYP2D6 7 (His324Pro) expressed by recombinant baculovirus in insect cells. Naunyn-Schmiedeberg's Archives of Pharmacology, 1997, 355, 309-318.	3.0	31
175	The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. British Journal of Clinical Pharmacology, 1997, 44, 439-446.	2.4	173
176	Extent and character of phenobarbital-mediated changes in gene expression in the liver. Molecular Pharmacology, 1997, 51, 363-9.	2.3	40
177	Immunohistochemical assessment of human microsomal epoxide hydrolase in primary and secondary liver neoplasm: a quantitative approach. Xenobiotica, 1996, 26, 107-116.	1.1	15
178	Nomenclature for human CYP2D6 alleles. Pharmacogenetics and Genomics, 1996, 6, 193-201.	5.7	403
179	Rapid detection of CYP2D6 null alleles by long distance-and multiplex-polymerase chain reaction. Pharmacogenetics and Genomics, 1996, 6, 417-421.	5.7	94
180	Truncated Human P450 2D6P: Expression in Escherichia coli, Ni2+-Chelate Affinity Purification, and Characterization of Solubility and Aggregation. Archives of Biochemistry and Biophysics, 1995, 321, 277-288.	3.0	54

#	Article	IF	Citations
181	The sequence of the 5'-end of the rat CYP17 gene, the transcription initiation site and a comparison with the homologous genes of other species. Molecular and Cellular Endocrinology, 1993, 95, 95-100.	3.2	8
182	Activation of CYP11A and CYP11B gene promoters by the steroidogenic cell-specific transcription factor, Ad4BP. Molecular Endocrinology, 1993, 7, 1196-1204.	3.7	114
183	Cooperating nonconsensus cAMP-responsive elements are mediators of adrenocorticotropin-induced VL30 transcription in steroidogenic adrenal cells. Journal of Biological Chemistry, 1993, 268, 3952-63.	3.4	20
184	Comparison of cAMP-responsive DNA sequences and their binding proteins associated with expression of the bovine CYP17 and CYP11A and human CYP21B genes. Journal of Steroid Biochemistry and Molecular Biology, 1992, 43, 931-935.	2.5	15
185	Distinct biochemical mechanisms for cAMPâ€dependent transcription of CYP17 and CYP21. FASEB Journal, 1992, 6, 719-723.	0.5	32
186	3',5'-cyclic adenosine monophosphate-dependent transcription of the CYP11A (cholesterol side chain) Tj ETQq0 0 0 rgBT /Overlock 10 T for transcription factor Sp1. Molecular Endocrinology, 1992, 6, 1682-1690.	3.7	33
187	Cytochrome P450IID subfamily in non-human primates. Biochemical Pharmacology, 1991, 41, 1657-1663.	4.4	16
188	[20] Immunoisolation of human microsomal cytochromes P450 using autoantibodies. Methods in Enzymology, 1991, 206, 201-209.	1.0	2
189	Activation of transcription in cell-free extracts by a novel cAMP-responsive sequence from the bovine CYP17 gene. Journal of Biological Chemistry, 1991, 266, 11417-20.	3.4	13
190	Patients with type ii autoimmune hepatitis express functionally intact cytochrome P-450 db1 that is inhibited by LKM-1 autoantibodiesin vitro but notin vivo. Hepatology, 1990, 12, 127-132.	7.3	89
191	The genetic polymorphism of debrisoquine/sparteine metabolismâ€"molecular mechanisms. , 1990, 46, 297-308.		99
192	Genetic Polymorphisms of Drug Metabolism. Advances in Drug Research, 1990, , 197-241.	0.8	39
193	The CYP2D gene subfamily: analysis of the molecular basis of the debrisoquine 4-hydroxylase deficiency in DA rats. Biochemistry, 1989, 28, 7349-7355.	2.5	95
194	Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature, 1988, 331, 442-446.	27.8	733
195	Absence of hepatic cytochrome P450bufl causes genetically deficient debrisoquine oxidation in man. Biochemistry, 1988, 27, 5447-5454.	2.5	156
196	Antibodies against human cytochrome P-450db1 in autoimmune hepatitis type II.. Proceedings of the National Academy of Sciences of the United States of America, 1988, 85, 8256-8260.	7.1	226
197	Debrisoquine/sparteine-type polymorphism of drug oxidation. Purification and characterization of two functionally different human liver cytochrome P-450 isozymes involved in impaired hydroxylation of the prototype substrate bufuralol. Journal of Biological Chemistry, 1986, 261, 11734-43.	3.4	87